The investment will be concentrated on three nonprofit Product Development Partnerships (PDPs) that are leading the global effort to develop new TB drugs, vaccines and diagnostics. This is the largest investment that any single country has made to research and development of new tools to combat the pandemic.

Over a 4 year period, DGIS is investing:

- 18.4 million euros in the Aeras Global TB Vaccine Foundation for preclinical work and clinical trials of two of the world’s most promising vaccine candidates to develop a more effective TB vaccine.

- 8 million euros in the Global Alliance for TB Drug Development (TB Alliance) to expand its portfolio of new, novel TB drug discovery projects; develop tools and processes to speed clinical development; and accelerate efforts at the country and global level for the introduction of new TB drug regimes

- 4 million euros in the Foundation for Innovative New Diagnostics (FIND) to accelerate the development, evaluation and demonstration of rapid diagnostic tests to detect TB in sputum and urine.

The announecment was made as experts discussed critical TB issues at the World Conference on Lung Health organised in Paris from 31 October to 4 November by the International Union Against Tuberculosis and Lung Disease.

Last modified on December 1 2006.